For the year ending 2025-12-31, TXG has $1,041,365K in assets. $245,039K in debts.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 473,966 | |||
| Marketable securities | 49,443 | |||
| Accounts receivable, net | 47,013 | |||
| Inventory | 56,341 | |||
| Other receivables | 35,480 | |||
| Prepaid expenses and other current assets | 22,208 | |||
| Total current assets | 684,451 | |||
| Property and equipment, net | 226,711 | |||
| Operating lease right-of-use assets | 60,450 | |||
| Goodwill | 4,511 | |||
| Intangible assets, net | 62,329 | |||
| Other noncurrent assets | 2,913 | |||
| Total assets | 1,041,365 | |||
| Accounts payable | 12,733 | |||
| Deferred revenue | 23,902 | |||
| Contingent consideration, current | 23,363 | |||
| Accrued compensation and related benefits | 42,500 | |||
| Accrued expenses and other current liabilities | 39,971 | |||
| Operating lease liabilities | 10,985 | |||
| Total current liabilities | 153,454 | |||
| Contingent consideration, noncurrent | 1,237 | |||
| Deferred revenue, noncurrent | 10,501 | |||
| Other noncurrent liabilities | 6,471 | |||
| Operating lease liabilities, noncurrent | 73,376 | |||
| Total liabilities | 245,039 | |||
| Common stock, 0.00001 par value 1,100,000,000 shares authorized (class a 1,000,000,000, class b 100,000,000) 127,691,329 (class a 117,612,457, class b 10,078,872) and 122,291,837 (class a 108,235,004, class b 14,056,833) shares issued and outstanding as of december31, 2025 and 2024, respectively | 2 | |||
| Additional paid-in capital | 2,306,690 | |||
| Accumulated deficit | -1,510,591 | |||
| Accumulated other comprehensive income (loss) | 225 | |||
| Total stockholders equity | 796,326 | |||
| Total liabilities and stockholders equity | 1,041,365 | |||
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)